Stockscreener 앱 받기
3.98
0.25%
0.010
시간 외 거래:
3.98
전일 마감가:
$3.97
열려 있는:
$3.96
하루 거래량:
268.08K
Relative Volume:
0.41
시가총액:
$235.20M
수익:
-
순이익/손실:
$-57.44M
주가수익비율:
-2.9788
EPS:
-1.3361
순현금흐름:
$-56.46M
1주 성능:
-3.16%
1개월 성능:
-2.93%
6개월 성능:
-39.24%
1년 성능:
+31.35%
1일 변동 폭
$3.93
$4.01
1주일 범위
$3.78
$4.03
52주 변동 폭
$2.97
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.98 | 234.61M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | JP Morgan | Overweight |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
모두보기
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat
Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView
Protara Therapeutics: Q2 Earnings Snapshot - AOL.com
Protara Posts $21.7 Million Q2 Loss as Pipeline Milestones Near - Quiver Quantitative
Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics Inc (TARA) Balance Sheet - TradingKey
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TARA|Protara Therapeutics Inc|Price:3.975|Chg%:+0.055 - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
TARA|Protara Therapeutics Inc|Price:3.938|Chg%:-0.102 - TradingKey
TARA|Protara Therapeutics Inc|Price:4.030|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA - MarketBeat
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Should I buy Protara Therapeutics (TARA) - zacks.com
Protara Therapeutics (TARA) Edges Higher, Approaches Key Resistance Amid Low VolumePCR Extreme - dars.gov.et
Protara Therapeutics Q1 2026 Earnings: Narrower Loss Amid Continued Clinical DevelopmentHigh Growth Earnings - dars.gov.et
What's Driving Protara's Recent Surge - Kavout | AI
Protara Therapeutics (TARA) Edges Higher by 2.86%, Testing Resistance Near $4.54Growth Stock Picks - dars.gov.et
Millennium Group and Israel Englander report 5.7% stake in Protara (TARA) - Stock Titan
Protara Therapeutics focuses on rare disease programs as development continues - Ad Hoc News
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - GlobeNewswire
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA) - TradingView
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up - TipRanks
Protara Therapeutics (TARA) Holds Steady Near Support, Faces Resistance at $4.26Shakeout Pattern - dars.gov.et
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA) - The Globe and Mail
Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts - Stock Titan
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – GETTEX:1KPA - TradingView
Protara Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (2026) - Minichart
Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com - Investing.com South Africa
Protara Therapeutics Announces Key Medical Leadership Transition - TipRanks
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protara Therapeutics Inc 주식 (TARA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shefferman Jesse | CEO and President |
Jun 29 '26 |
Sale |
4.09 |
215,687 |
882,160 |
721,832 |
1.80%
1.77%
자본화:
|
볼륨(24시간):